0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial

We determined the efficacy and safety of 0.1% RGN-259 ophthalmic solution (containing the regenerative protein thymosin ß4) in promoting the healing of persistent epithelial defects in patients with Stages 2 and 3 neurotrophic keratopathy. Complete healing occurred after 4 weeks in 6 of the 10 RGN-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Sosne, Gabriel, Kleinman, Hynda K., Springs, Clark, Gross, Robert Hollis, Sung, Jihye, Kang, Shinwook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820614/
https://www.ncbi.nlm.nih.gov/pubmed/36613994
http://dx.doi.org/10.3390/ijms24010554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820614/
https://www.ncbi.nlm.nih.gov/pubmed/36613994
http://dx.doi.org/10.3390/ijms24010554

Ejemplares similares